

**THE COST OF CRITICAL LIMB ISCHEMIA**

Mary L. Yost  
404-520-6652  
THE SAGE GROUP

THE SAGE GROUP, LLC  
RESEARCH AND CONSULTING  
23 Ridge Rd  
Beaufort SC 29907

Copyright Pending  
2019

All rights reserved, including the right of reproduction  
in whole or in part in any form.

## INDEX OF TABLES

Table 1: Critical Limb Ischemia 2018 Cardiovascular Costs	6.
Table 2: Critical Limb Ischemia 2018 All-Cause Costs	7.
Table 3: Critical Limb Ischemia 2018 All-Cause Costs Calculated by CLI Only Costs Plus Non-CLI Costs	8.
Table 4: Critical Limb Ischemia Components of Direct Costs	10.
Table 5: Critical Limb Ischemia Interventional and Cardiovascular Cost Components	11.
Table 6: Cardiovascular and All-Cause Cost of Critical Limb Ischemia	13.
Table 7: 2018 Cost of Critical Limb Ischemia in Patients Undergoing Interventional Therapy	14.
Table 8: Critical Limb Ischemia Cost Estimates for Interventional and Non-Interventional Treatments	16.
Table 9: 2018 Per Patient Costs by Type of Intervention	17.
Table 10: Components of Total Hospital Costs	20.
Table 11: Perioperative Mortality by Procedure	20.
Table 12: Three Most Common Operative Morbidities Associated with Major Amputation, Bypass Surgery and Endovascular	21.
Table 13: Critical Limb ischemia 4-Year Amputation Rates by Disease Severity	26.
Table 14: Critical Limb ischemia 4-Year Mortality Rates by Disease Severity	26.
Table 15: 2018 Critical Limb ischemia Treatment Costs by Disease Severity	27.
Table 16: Peripheral Artery Disease Total Costs of Endovascular Procedures by Type and Setting	29.
Table 17: Critical Limb Ischemia Prevalence of Coronary and Cerebrovascular Disease in Published Studies	33.
Table 18 Critical Limb Ischemia Estimated Prevalence of Coronary Artery Disease (CAD), Congestive Heart Failure (CHF) and Cerebrovascular Disease (CVD)	34.
Table 19: Peripheral Artery Disease Additional Cost of Major Adverse cardiac Events (MACE) per Patient	36.
Table 20: Critical Limb Ischemia 2018 Incremental Cost of Major Adverse Cardiac Events (MACE)	37.

Table 21: Critical Limb Ischemia Undertreatment of Cardiovascular Risk Factors	37.
Table 22: Critical Limb Ischemia Direct Costs Associated with Treatment of Modifiable Cardiovascular Risk Factors	40.
Table 23: Critical Limb Ischemia 2018 Incremental Cost of Major Adverse Leg Events (MALE)	41.
Table 24: Diabetes Increases the Risk of Amputation in Critical Limb Ischemia	44.
Table 25: Estimated Critical Limb Ischemia Costs in Patients with and without Diabetes	45.
Table 26: Cost of Diabetic Foot Ulcers in Critical Limb Ischemia Patients	48.
Table 27: Critical Limb Ischemia All-Cause Readmissions	49.
Table 28: Critical Limb Ischemia Mortality, Revascularization and Major Amputation Rates Comparison of Planned and Unplanned Readmissions	52.
Table 29: Critical Limb Ischemia Per Patient Cost of Readmissions	52.
Table 30: Critical Limb Ischemia Most Common Reasons for 30-Day All-Cause Readmissions	54.
Table 31: Percentage of Critical Limb Ischemia Patients in Medicare Undergoing Single and Multiple Revascularization and Major Amputation Procedures	56.

## INDEX OF FIGURES

Figure 1: Hospital Costs of Major Amputation Exceed Those of Revascularization	19.
Figure 2: 2012 Total Costs of Major Amputation, Bypass Surgery and Endovascular	22.
Figure 3: Three-Year Ischemic Outcomes Minor Amputation Compared with Above-Knee-Amputation	24.
Figure 4: 2018 Total Direct Costs of Amputation by Type	25.
Figure 5: Cardiovascular Disease Direct and Indirect Costs Associated with Number of Modifiable Cardiovascular Risk Factors	39.
Figure 6: Percentage of the U.S. Adult Population and Critical Limb Ischemia Population with Diabetes	42.
Figure 7: Comparison of 30-Day and 1-Year Readmission Rates for Critical Limb Ischemia and Intermittent Claudication	50.
Figure 8: 30-Day All-Cause Readmission Rate Increases with Severity of Critical Limb Ischemia	51.

## CONTACT INFORMATION

Mary L. Yost  
President  
Telephone (404) 520-6652  
[yost@thesagegroup.us](mailto:yost@thesagegroup.us)